|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuebler JP, Wieand HS, O'Connell MJ, Smith
RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE,
Atkins JN, et al: Oxaliplatin combined with weekly bolus
fluorouracil and leucovorin as surgical adjuvant chemotherapy for
stage II and III colon cancer: Results from NSABP C-07. J Clin
Oncol. 25:2198–2204. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patel K, Gadewar M, Tripathi R, Prasad SK
and Patel DK: A review on medicinal importance, pharmacological
activity and bioanalytical aspects of beta-carboline alkaloid
ʻHarmineʼ. Asian Pac J Trop Biomed. 2:660–664. 2012. View Article : Google Scholar
|
|
4
|
Hamsa TP and Kuttan G: Harmine inhibits
tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP
and pro-inflammatory mediators both in vivo and in vitro. Eur J
Pharmacol. 649:64–73. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao L and Wink M: The β-carboline
alkaloid harmine inhibits telomerase activity of MCF-7 cells by
down-regulating hTERT mRNA expression accompanied by an accelerated
senescent phenotype. PeerJ. 1:e1742013. View Article : Google Scholar
|
|
6
|
Hamsa TP and Kuttan G: Harmine activates
intrinsic and extrinsic pathways of apoptosis in B16F-10 melanoma.
Chin Med. 6:112011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lala S, Pramanick S, Mukhopadhyay S,
Bandyopadhyay S and Basu MK: Harmine: Evaluation of its
antileishmanial properties in various vesicular delivery systems. J
Drug Target. 12:165–175. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hudson JB, Graham EA and Towers GH:
Antiviral effect of harmine, a photoactive beta-carboline alkaloid.
Photochem Photobiol. 43:21–26. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Göckler N, Jofre G, Papadopoulos C, Soppa
U, Tejedor FJ and Becker W: Harmine specifically inhibits protein
kinase DYRK1A and interferes with neurite formation. FEBS J.
276:6324–6337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dai F, Chen Y, Song Y, Huang L, Zhai D,
Dong Y, Lai L, Zhang T, Li D, Pang X, et al: A natural small
molecule harmine inhibits angiogenesis and suppresses tumour growth
through activation of p53 in endothelial cells. PLoS One.
7:e521622012. View Article : Google Scholar
|
|
11
|
Cao MR, Li Q, Liu ZL, Liu HH, Wang W, Liao
XL, Pan YL and Jiang JW: Harmine induces apoptosis in HepG2 cells
via mitochondrial signaling pathway. Hepatobiliary Pancreat Dis
Int. 10:599–604. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boeira JM, Viana AF, Picada JN and
Henriques JA: Genotoxic and recombinogenic activities of the two
beta-carboline alkaloids harman and harmine in Saccharomyces
cerevisiae. Mutat Res. 500:39–48. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Sun K, Ding J, Xu H, Zhu L, Zhang
K, Li X and Sun W: Harmine induces apoptosis and inhibits tumor
cell proliferation, migration and invasion through down-regulation
of cyclooxy-genase-2 expression in gastric cancer. Phytomedicine.
21:348–355. 2014. View Article : Google Scholar
|
|
14
|
Yang X, Wang W, Qin JJ, Wang MH, Sharma H,
Buolamwini JK, Wang H and Zhang R: JKA97, a novel benzylidene
analog of harmine, exerts anti-cancer effects by inducing G1
arrest, apoptosis, and p53-independent up-regulation of p21. PLoS
One. 7:e343032012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song Y, Kesuma D, Wang J, Deng Y, Duan J,
Wang JH and Qi RZ: Specific inhibition of cyclin-dependent kinases
and cell proliferation by harmine. Biochem Biophys Res Commun.
317:128–132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang W, Liao XL, Chen JH, Li DD, Lin CL,
Yan YX, Tang YH and Jiang JW: Sodium valproate induces
mitochondria-dependent apoptosis in human hepatoblastoma cells.
Chin Med J. 124:2167–2172. 2011.PubMed/NCBI
|
|
17
|
Tan ML, Ooi JP, Ismail N, Moad AI and
Muhammad TS: Programmed cell death pathways and current antitumor
targets. Pharm Res. 26:1547–1560. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qin S, Yang C, Li S, Xu C, Zhao Y and Ren
H: Smac: Its role in apoptosis induction and use in lung cancer
diagnosis and treatment. Cancer Lett. 318:9–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou F, Yang Y and Xing D: Bcl-2 and
Bcl-xL play important roles in the crosstalk between autophagy and
apoptosis. FEBS J. 278:403–413. 2011. View Article : Google Scholar
|
|
20
|
Sánchez I and Dynlacht BD: New insights
into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol.
16:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Besson A, Dowdy SF and Roberts JM: CDK
inhibitors: Cell cycle regulators and beyond. Dev Cell. 14:159–169.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Berry LD and Gould KL: Regulation of Cdc2
activity by phosphorylation at T14/Y15. Prog Cell Cycle Res.
2:99–105. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fattaey A and Booher RN: Myt1: A Wee1-type
kinase that phosphorylates Cdc2 on residue Thr14. Prog Cell Cycle
Res. 3:233–240. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tait SW and Green DR: Mitochondria and
cell death: Outer membrane permeabilization and beyond. Nat Rev Mol
Cell Biol. 11:621–632. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Faes S and Dormond O: PI3K and AKT:
Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang X, Tang N, Hadden TJ and Rishi AK:
Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta.
1813:1978–1986. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo J: Glycogen synthase kinase 3beta
(GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett.
273:194–200. 2009. View Article : Google Scholar
|
|
30
|
Phukan S, Babu VS, Kannoji A, Hariharan R
and Balaji VN: GSK3beta: Role in therapeutic landscape and
development of modulators. Br J Pharmacol. 160:1–19. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Samatar AA and Poulikakos PI: Targeting
RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug
Discov. 13:928–942. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peng S, Zhang Y, Zhang J, Wang H and Ren
B: ERK in learning and memory: A review of recent research. Int J
Mol Sci. 11:222–232. 2010. View Article : Google Scholar : PubMed/NCBI
|
